Trials / Completed
CompletedNCT00843284
Symptomatic Treatment Of Patients With Neuropathic Pain With LYRICA
Assessing the Treatment of Patients With Neuropathic Pain Using LYRICA; A Non Interventional Post-marketing Study (NI-PMS)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 691 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Non-Interventional, Post-Marketing Surveillance (NI-PMS) study whose objectives were to assess the impact of pregabalin on subjects' pain, quality of sleep, and their general wellbeing, as well as the tolerance and safety of pregabalin in subjects with neuropathic pain.
Detailed description
A non-interventional study of patients diagnosed with neuropathic pain administered pregabalin and followed up for 8 weeks
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pregabalin | Capsules, 150 - 600 mg/day, 2-3 times/day, 8 weeks |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2008-03-01
- Completion
- 2008-03-01
- First posted
- 2009-02-13
- Last updated
- 2021-02-10
- Results posted
- 2009-04-16
Source: ClinicalTrials.gov record NCT00843284. Inclusion in this directory is not an endorsement.